Hikma Pharmaceuticals Regulatory News (HIK)

6 Dec 2006 17:37

Hikma Pharmaceuticals Plc06 December 2006 Update on Non-Executive Director's Appointments LONDON, 6 December 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK), themultinational pharmaceuticals group, announces that Michael Ashton, anon-executive Director and Chairman of the Remuneration Committee, has beenappointed as the Chief Executive Officer of LMA International NV, a Singaporelisted company. - ENDS -Enquiries: Hikma Pharmaceuticals PLCSusan Ringdal +44 20 7399 2760Investor Relations Director Brunswick GroupJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About HikmaHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange